Company United Therapeutics Corporation

Equities

UTHR

US91307C1027

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sales per region

Ratings for United Therapeutics Corporation

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 02:23:30 2024-05-28 pm EDT			5-day change	1st Jan Change
268.2 ^USD	-1.70%		-2.77%	+21.68%

May. 16	United Therapeutics Insider Sold Shares Worth $545,800, According to a Recent SEC Filing	MT
May. 14	United Therapeutics Insider Sold Shares Worth $1,911,532, According to a Recent SEC Filing	MT

United Therapeutics Corporation is a pharmaceutical company. It markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection (Unituxin) for treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin (Remunity). Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKindâs Afrezza (insulin human) Inhalation Powder.

Number of employees: 1,168

USD in Million	2022	Weight	2023	Weight	Delta
Pharmaceutical 100.0 %	1,936	100.0 %	2,328	100.0 %	+20.20%

USD in Million	2022	Weight	2023	Weight	Delta
United States 94.6 %	1,814	93.7 %	2,202	94.6 %	+21.39%
Rest of World 5.4 %	122	6.3 %	125	5.4 %	+2.54%

Managers	Title	Age	Since
Martine Rothblatt CEO	Chief Executive Officer	69	96-06-25
Michael Benkowitz PSD	President	52	11-03-31
James Edgemond DFI	Director of Finance/CFO	56	12-12-31
Dewey Steadman IRC	Investor Relations Contact	-	-
Paul Mahon LAW	General Counsel	60	96-06-25

Members of the board	Title	Age	Since
Raymond Kurzweil BRD	Director/Board Member	76	01-12-31
Martine Rothblatt CEO	Chief Executive Officer	69	96-06-25
Tommy Thompson BRD	Director/Board Member	81	09-12-31
Judy Olian BRD	Director/Board Member	72	15-06-25
Katherine Klein BRD	Director/Board Member	67	14-11-10
Louis Sullivan BRD	Director/Board Member	90	01-12-31
Christopher Patusky BRD	Director/Board Member	60	02-10-23
Christopher Causey BRD	Director/Board Member	61	02-12-31
Richard Giltner BRD	Director/Board Member	60	09-04-28
Nilda Mesa BRD	Director/Board Member	64	18-10-30

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	74,250,109	43,536,223 ( 58.63 %)	29,894,415 ( 40.26 %)	58.63 %

Name	Equities	%	Valuation
BlackRock Advisors LLC 10.70 %	5,037,364	10.70 %	1 189 M $
Vanguard Fiduciary Trust Co. 9.952 %	4,683,095	9.952 %	1 105 M $
Wellington Management Co. LLP 7.251 %	3,412,260	7.251 %	805 M $
Martine Rothblatt 6.750 %	3,176,439	6.750 %	749 M $
Avoro Capital Advisor LLC 6.075 %	2,858,888	6.075 %	675 M $
Renaissance Technologies LLC 4.572 %	2,151,714	4.572 %	508 M $
STATE STREET CORPORATION 4.112 %	1,935,119	4.112 %	457 M $
Fidelity Management & Research Co. LLC 2.161 %	1,016,988	2.161 %	240 M $
AQR Capital Management LLC 1.800 %	846,955	1.800 %	200 M $
Geode Capital Management LLC 1.760 %	828,271	1.760 %	195 M $

Name	Equities	%	Valuation
CELULARITY INC. 3.66%	796,885	3.66%	2,446,437 $
CLENE INC. 2.23%	2,869,517	2.23%	995,722 $

United Therapeutics Corp.

1000 Spring Street

20910, Silver Spring

+301 608 9292

http://www.unither.com

address United Therapeutics Corporation(UTHR)

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

272.9 USD

Average target price

294.2 USD

Spread / Average Target

+7.80%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
UNITED THERAPEUTICS CORPORATION	+22.76%	12.11B
MODERNA, INC.	+54.76%	63.85B
IQVIA HOLDINGS INC.	-1.63%	41.83B
LONZA GROUP AG	+41.33%	40.47B
CELLTRION, INC.	-10.02%	27.17B
ICON PUBLIC LIMITED COMPANY	+12.95%	26.52B
ALNYLAM PHARMACEUTICALS, INC.	-20.56%	18.69B
BIO-TECHNE CORPORATION	+2.86%	12.73B
MEDPACE HOLDINGS, INC.	+28.65%	12.07B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-8.46%	11.19B

Other Biotechnology & Medical Research